ArticleFrontiers in oncology2026
Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aromatase inhibitors have been successfully employed in clinical practice for the treatment of breast cancer (BC); however, the accompanying tendon disorders has often been underestimated. This study aimed to conduct a comprehensive empirical investigation and assess tendon disorders associated with third-generation aromatase inhibitors using data from the FDA's FAERS database. The goal was to provide a theoretical foundation for the rational application of these drugs in clinical settings. Methods: Reports of tendon disorders related to third-generation aromatase inhibitors were retrieved from the FAERS database, covering the period from the first quarter of 2004 to the first quarter of 2024. The data were further analyzed using proportional analysis and a Bayesian approach to detect signals of tendon disorders induced by the three drugs. Additionally, the clinical characteristics, onset time, correlation, and stratification analysis of tendon disorders associated with the three drugs were examined. Results: Positive signals for tendon disorders associated with third-generation aromatase inhibitors were identified. At the preferred term (PT) level, twelve positive signals were detected, with trigger finger and tenosynovitis stenosans presenting a significant signal. In terms of onset time, letrozole exhibited the earliest onset at 74 days, whereas exemestane showed the latest onset at 243.5 days. After excluding the effect of combination drugs, a clear association between third-generation aromatase inhibitors and tendon disorders was observed. Conclusion: Analysis of the FAERS database has identified risk trends for tendon disorders associated with third-generation aromatase inhibitors. Furthermore, the study reveals varying degrees of tendon toxicity related to these inhibitors, including distinct time-to-onset profiles and drug-specific signal intensities, providing valuable insights into associated tendon disorders in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.